JAVELIN PARP medley: A phase Ib/II study of avelumab (anti-PD-L1) plus talazoparib in locally advanced or metastatic solid tumors

T. A. Yap; J. T. Beck; R. A. Stewart; S. C. Dahm; C. Chappey; R. Cesari; A. Scheuber; M. D. Galsky; D. Wise

doi:10.1093/annonc/mdy288.112

JAVELIN PARP medley: A phase Ib/II study of avelumab (anti-PD-L1) plus talazoparib in locally advanced or metastatic solid tumors

T. A. Yap, J. T. Beck, R. A. Stewart, S. C. Dahm, C. Chappey, R. Cesari, A. Scheuber, M. D. Galsky, D. Wise

Investigational Cancer Therapeutics

Research output: Contribution to journal › Article › peer-review

Original language	English (US)
Pages (from-to)	viii441
Journal	Annals of oncology : official journal of the European Society for Medical Oncology
Volume	29
DOIs	https://doi.org/10.1093/annonc/mdy288.112
State	Published - Oct 1 2018

ASJC Scopus subject areas

Hematology
Oncology

Access to Document

10.1093/annonc/mdy288.112

Cite this

Yap, T. A., Beck, J. T., Stewart, R. A., Dahm, S. C., Chappey, C., Cesari, R., Scheuber, A., Galsky, M. D., & Wise, D. (2018). JAVELIN PARP medley: A phase Ib/II study of avelumab (anti-PD-L1) plus talazoparib in locally advanced or metastatic solid tumors. Annals of oncology : official journal of the European Society for Medical Oncology, 29, viii441. https://doi.org/10.1093/annonc/mdy288.112

Yap, TA, Beck, JT, Stewart, RA, Dahm, SC, Chappey, C, Cesari, R, Scheuber, A, Galsky, MD & Wise, D 2018, 'JAVELIN PARP medley: A phase Ib/II study of avelumab (anti-PD-L1) plus talazoparib in locally advanced or metastatic solid tumors', Annals of oncology : official journal of the European Society for Medical Oncology, vol. 29, pp. viii441. https://doi.org/10.1093/annonc/mdy288.112

@article{d253c508f9d843f2b6abdedc3af8cb6e,

title = "JAVELIN PARP medley: A phase Ib/II study of avelumab (anti-PD-L1) plus talazoparib in locally advanced or metastatic solid tumors",

author = "Yap, {T. A.} and Beck, {J. T.} and Stewart, {R. A.} and Dahm, {S. C.} and C. Chappey and R. Cesari and A. Scheuber and Galsky, {M. D.} and D. Wise",

year = "2018",

month = oct,

day = "1",

doi = "10.1093/annonc/mdy288.112",

language = "English (US)",

volume = "29",

pages = "viii441",

journal = "Annals of oncology : official journal of the European Society for Medical Oncology",

issn = "0923-7534",

publisher = "Oxford University Press",

}

TY - JOUR

T1 - JAVELIN PARP medley

T2 - A phase Ib/II study of avelumab (anti-PD-L1) plus talazoparib in locally advanced or metastatic solid tumors

AU - Yap, T. A.

AU - Beck, J. T.

AU - Stewart, R. A.

AU - Dahm, S. C.

AU - Chappey, C.

AU - Cesari, R.

AU - Scheuber, A.

AU - Galsky, M. D.

AU - Wise, D.

PY - 2018/10/1

Y1 - 2018/10/1

UR - http://www.scopus.com/inward/record.url?scp=85081532285&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85081532285&partnerID=8YFLogxK

U2 - 10.1093/annonc/mdy288.112

DO - 10.1093/annonc/mdy288.112

M3 - Article

C2 - 32137126

SN - 0923-7534

VL - 29

SP - viii441

JO - Annals of oncology : official journal of the European Society for Medical Oncology

JF - Annals of oncology : official journal of the European Society for Medical Oncology

ER -

JAVELIN PARP medley: A phase Ib/II study of avelumab (anti-PD-L1) plus talazoparib in locally advanced or metastatic solid tumors

ASJC Scopus subject areas

Access to Document

Other files and links

Cite this